Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05231122CT.gov Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
NCT05920798CT.gov Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | — | Recruiting | — | — | — |
NCT04919629CT.gov APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | — | Recruiting | — | — | — |
NCT05446298CT.gov ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT05446870CT.gov Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | — | Completed | — | — | — |
NCT05329532CT.gov Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | — | Recruiting | — | — | — |
NCT05114421CT.gov Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04099277CT.gov A Study of LY3435151 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT05188781CT.gov Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT03311334CT.gov A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02853318CT.gov Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Roswell Park Cancer Institute | P2 | BB · 67 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Defactinib | Verastem, Inc. | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P3 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-ovarian-serous-adenocarcinoma-59457
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →